Control of the ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will require one or more vaccines. Currently, numerous SARS-CoV-2 vaccines are in either pre-clinical or clinical development. Twenty are in fase III development. In this review we summarise available safety and efficacy data of two RNA based vaccines, two non-replication competent vector-based vaccine, one inactivated whole-virus vaccine, and one subunit. All being either approved or nearing approval.